Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Rx-to-OTC switch applications

This article was originally published in The Tan Sheet

Executive Summary

Rx-to-OTC switch applications: Representatives from FDA's Center for Drug Evaluation and Research told PhRMA board members Feb. 8 that the agency's internal reform efforts include developing written procedures for OTC switches. In a section-by-section analysis of draft FDA reform legislation circulated last summer, PhRMA pointed out the confusion at FDA prior to the creation of the now defunct Office of OTC Drug Evaluation regarding authority over Rx-to-OTC switch applications ("The Tan Sheet" July 17, 1995, p. 23). PhRMA's original draft legislation for FDA reform included a provision that would have retained office status for OTC drugs...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel